Crizotinib Continuation Clinical Study
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE4
Clinical Trials Related to NSCLC
Related studies linked through entity extraction aliases.
Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation
- Status
- COMPLETED
- Phase
- PHASE2
Lorlatinib Continuation Study
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE4
Neoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung Adenocarcinoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Study of HA121-28 in Patients With Non-Small Cell Lung Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
First in Human Study of TORL-1-23 in Participants With Advanced Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Radiation During Osimertinib Treatment: a Safety and Efficacy Cohort Study
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Phase II Clinical Trial to Evaluate HLX208 in Advanced Non-small Cell Lung Cancer Patients With BRAF V600 Mutation
- Status
- UNKNOWN
- Phase
- PHASE2
Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)
- Status
- COMPLETED
- Phase
- PHASE2
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Tislelizumab in Addition to BACE in Patients with NSCLC
- Status
- COMPLETED
- Phase
- PHASE2
Whether Sputum Can Serve as an Alternative Source for Liquid Biopsy in Patients With Lung Cancer
- Status
- COMPLETED
- Phase
- N/A
A Study to Evaluate the Efficacy of Osimertinib With Early Intervention SRS Treatment Compared to the Continuation of Osimertinib Alone, in Patients With EGFR Mutated NSCLC and Asymptomatic Brain Metastases
- Status
- RECRUITING
- Phase
- NA
Toripalimab Combined With Anlotinib and SBRT in Patients With Untreated Brain Metastases of Driven Gene-negative NSCLC
- Status
- COMPLETED
- Phase
- PHASE1
A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC
- Status
- WITHDRAWN
- Phase
- PHASE2
A Phase II Trial of Camrelizumab Combined With Famitinib for Adjuvant Treatment of Stage II-IIIA NSCLC.
- Status
- UNKNOWN
- Phase
- PHASE2
JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2